PAM
CASC

Panagora Asset Management’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Panagora Asset Management’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-12,868
Closed -$53K – 2407
2017
Q3 		$53K Hold
12,868
– – ﹤0.01% 2042
2017
Q2 		$48K Buy
+12,868
New +$51.1K ﹤0.01% 2084
2016
Q1 		– Sell
-7,372
Closed -$98K – 2382
2015
Q4 		$98K Buy
7,372
+4,618
+168% +$79.5K ﹤0.01% 1807
2015
Q3 		$45K Buy
2,754
+45
+2% +$923 ﹤0.01% 2021
2015
Q2 		$61K Buy
+2,709
New +$42.8K ﹤0.01% 2096
2014
Q2 		– Sell
-21,230
Closed -$381K – 2429
2014
Q1 		$381K Buy
+21,230
New +$349K ﹤0.01% 1526

Other funds holding CASC

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
SH
Sandia Holdings Greenwich, Connecticut $213M AUM 29.35% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Panagora Asset Management's CASC Position: Q4 2017 in Review

Panagora Asset Management sold out of Cascadian Therapeutics, Inc. (CASC) in Q4 2017, closing a stake of 12,868 shares — an estimated $53K sold.

Panagora Asset Management first reported a position in CASC in Q1 2014 and held it in 6 quarters. The position peaked at $381K in Q1 2014. 91 funds tracked by Wall St. Rank hold CASC as of Q4 2017.

  • Panagora Asset Management reported no remaining Cascadian Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
  • Panagora Asset Management sold 12,868 Cascadian Therapeutics, Inc. shares in Q4 2017, an estimated $53K.
  • Panagora Asset Management first reported a position in Cascadian Therapeutics, Inc. in Q1 2014 and held it in 6 quarters.
  • Panagora Asset Management's Cascadian Therapeutics, Inc. position peaked at $381K in Q1 2014.
  • 91 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q4 2017.

Based on Panagora Asset Management's 13F filing for Q4 2017, filed 14 Feb 2018.